Janssen COVID-19 Vaccine

On February 27, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

FDA Statement on Vaccines

Following today’s positive advisory committee meeting outcome regarding the Janssen Biotech Inc. COVID-19 Vaccine, the U.S. Food and Drug Administration has informed the sponsor that it will rapidly work toward finalization and issuance of an emergency use authorization.

Caring for the Caregivers — Covid-19 Vaccination for Essential Members of the Health Care Team

As U.S. states have developed guidelines for Covid-19 vaccination, some have moved to include “paid or unpaid caregivers (including parents or foster parents) of medically fragile children or adults who live at home” in Phase 1 vaccine allocation.

Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines

Two doses of the Pfizer and Moderna COVID-19 vaccines are necessary to confer adequate immunity. The new vaccines for coronavirus disease 2019 (COVID-19) are highly effective, but controversy exists about whether a second dose should be delayed in order to immunize more people. The second dose is necessary and should be given.

Did you have COVID-19? You could be reinfected by new variants

People who already were infected with COVID-19 could face reinfection if the new coronavirus variants become the dominant strains, Dr. Anthony Fauci said Monday.